South Korea: Researchers have found in a new study that among patients with type 2 diabetes not using insulin or thiazolidinediones, higher ketone body levels within a mild hyperketonemic range were associated with better kidney outcomes. Those in the highest ketone tertile had a 37% lower risk of major adverse kidney events compared with those in the lowest tertile. The lowest kidney risk was seen at ketone levels of approximately 300–400 µmol/L, suggesting a potentially protective association between mild ketosis and kidney health.

The findings, published in Diabetes Research and Clinical Practice by Soo Myoung Shin of the Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea, and colleagues, examined whether circulating ketone body concentrations were associated with subsequent kidney and cardiovascular complications in people with type 2 diabetes.
The prospective cohort included 1,392 clinically stable patients with type 2 diabetes who were not receiving insulin or thiazolidinedione treatment. Researchers measured total serum ketone body concentrations during stable outpatient visits and divided participants into three groups according to their ketone levels: 0.08–92.3, 92.7–170.8, and 171.0–1629.6 µmol/L.
Kidney outcomes assessed during follow-up included the development of macroalbuminuria, a decline in estimated glomerular filtration rate (eGFR) of at least 40%, and end-stage kidney disease. Cardiovascular events included myocardial infarction, coronary revascularization, ischemic stroke, hospitalization for heart failure, and cardiovascular death.
Over a median follow-up of 23.2 months, researchers recorded 158 kidney events and 64 cardiovascular events.
The following were the key findings:
  • The highest ketone tertile was associated with a 54% lower risk of a ≥40% decline in eGFR compared with the lowest tertile (aHR, 0.46).
  • Higher ketone levels were linked to a 37% lower risk of composite adverse kidney outcomes.
  • Among participants with baseline eGFR ≥60 mL/min/1.73 m², the risk of developing chronic kidney disease was 50% lower in the highest ketone group.
  • Higher ketone levels showed favorable trends for cardiovascular outcomes, but the associations were not statistically significant.
  • Overall, mildly elevated ketone levels were associated with better kidney outcomes in patients with type 2 diabetes who were not using insulin or thiazolidinediones.
  • Because the study was observational, the findings do not establish that higher ketone levels directly protect against kidney disease.
Overall, the results raise the possibility that mild hyperketonemia may serve as a marker or mediator of reduced kidney risk in type 2 diabetes, warranting further research to clarify the underlying mechanisms and determine whether modifying ketone body levels could have clinical implications.
Reference:
Shin, S. M., Lee, J., Kim, Y., Kim, J. A., Kim, K. J., Kim, K. J., Kim, H. Y., Kim, S. G., & Kim, N. H. (2026). Serum ketone body levels and risk of incident kidney and cardiovascular events among patients with type 2 diabetes: A prospective cohort study. Diabetes Research and Clinical Practice, 239, 113476. https://doi.org/10.1016/j.diabres.2026.113476


Tags:    
Article Source : Diabetes Research and Clinical Practice

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .